Evidence map›Paper›PMID 26574498›Full record

ArticleJournal of feline medicine and surgery2017

Effect of deslorelin on testicular function, serum dihydrotestosterone and oestradiol concentrations during and after suppression of sexual activity in tom cats.

Nilgün Gültiken, Selim Aslan, Serhan Serhat Ay, Mustafa Yavuz Gülbahar, Julianna Thuróczy, Ece Koldaş, Duygu Kaya, Murat Fındık, Sabine Schäfer-Somi

Open access · greenAbstract readControlled Clinical Trial
In one paragraph

Article in Journal of feline medicine and surgery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 4 countries.

Nilgün Gültiken1 Department of Obstetrics and Gynecology, Faculty of Veterinary Medicine, University of Ondokuz Mayis, Samsun, Turkey.
Selim Aslan2 Department of Obstetrics and Gynecology, Faculty of Veterinary Medicine, Near East University, Nicosia, North Cyprus.
Serhan Serhat Ay1 Department of Obstetrics and Gynecology, Faculty of Veterinary Medicine, University of Ondokuz Mayis, Samsun, Turkey.
Mustafa Yavuz Gülbahar3 Department of Pathology, Faculty of Veterinary Medicine, University of Ondokuz Mayis, Samsun, Turkey.
Julianna Thuróczy4 Department of Obstetrics and Gynecology, Faculty of Veterinary Science, Szent Istvan University, Budapest, Hungary.
Ece Koldaş1 Department of Obstetrics and Gynecology, Faculty of Veterinary Medicine, University of Ondokuz Mayis, Samsun, Turkey.
Duygu Kaya5 Department of Obstetrics and Gynecology, Faculty of Veterinary Medicine, University of Kafkas, Kars, Turkey.
Murat Fındık1 Department of Obstetrics and Gynecology, Faculty of Veterinary Medicine, University of Ondokuz Mayis, Samsun, Turkey.
Sabine Schäfer-Somi6 Centre for Artificial Insemination and Embryo Transfer, University of Veterinary Medicine, Vienna, Austria.
Ondokuz Mayıs University · TRKafkas University · TRMagyar Agrár- és Élettudományi Egyetem · HUNear East University · CYUniversity of Veterinary Medicine Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives The aim of the study was to evaluate the efficacy of a 4.7 mg deslorelin implant in tom cats. Methods Nine mature male cats were included in the deslorelin group and five cats in the control group. Before the study started, all cats were confirmed to have distinct sexually dimorphic behaviour. Blood samples were taken on the implantation day, at day 7 and at day 15, then monthly, in order to measure serum dihydrotestosterone (DHT) and 17beta(β)-oestradiol concentrations. The deslorelin group (n = 9) was divided into two subgroups: five cats (cats 1-5) were neutered in the postimplantation period during suppression of sexually dimorphic behaviour, and four cats (cats 6-9) were neutered after re-expression of sexually dimorphic behaviour. The control group cats (n = 5) were castrated without administration of the implant. Results Sexually dimorphic behaviours ceased within a mean ± SD of 13-58 days (23.30 ± 14.17) after implantation. DHT concentration decreased within 30 days. The mean duration of suppression was 26.5 ± 7.42 months and reactivation coincided with increased DHT values reaching preimplantation concentrations within 1 month. 17β-oestradiol concentrations significantly correlated with DHT concentrations ( P <0.01). For cats castrated during suppression of sexual behaviour, the length of the long axes of the nuclei of Leydig cells, the diameter of seminiferous tubules and the height of the epithelium of the seminiferous tubules did not change until 3-6 months after implantation, whereas at 12 and 32 months the measured values were even lower than in the control group. For cats castrasted after reactivation, the length of long axes of the nuclei of Leydig cells and the diameter of seminiferous tubules approached the values of the control group between 4 and 6 months after reactivation. Conclusions and relevance A deslorelin implant (4.7 mg) suppresses sexually dimorphic behaviour in tom cats without any side effects and with full reversibility; however, duration of suppression is highly individual.

Indexed as

AnimalsCatsDihydrotestosteroneDrug ImplantsEnzyme InhibitorsEstradiolGonadotropin-Releasing HormoneMaleSexual Behavior, AnimalTestisTreatment OutcomeTriptorelin PamoatedeslorelinDihydrotestosteroneDrug ImplantsEnzyme InhibitorsEstradiolGonadotropin-Releasing HormoneTriptorelin Pamoate

Identifiers

PMID26574498
PMCPMC10816557
OpenAlexW2282692142

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.